Hypertension
Three international guidelines are covered. AHA/ACC 2025 and ESC 2024 are the newest. ISH 2020 is older but is written for low- and middle-income settings, which makes it useful in Bangladesh, where no current national hypertension guideline is published online.
Where they agree
- First-line drugs: ACE inhibitor or ARB, long-acting dihydropyridine CCB, and thiazide or thiazide-like diuretic. Beta-blockers are added only for a compelling indication such as angina, post-MI, HFrEF or rate control.
- Start with two drugs for most people with BP ≥140/90, ideally in a single pill.
- Never combine an ACE inhibitor with an ARB.
- Confirm the diagnosis with out-of-office BP (home or ambulatory) when possible.
- Resistant hypertension: after ACEi/ARB + CCB + thiazide-like diuretic, the fourth drug is spironolactone.
- Lifestyle for everyone: cut salt, follow a DASH/Mediterranean-style diet, lose weight, exercise and limit alcohol.
Where they differ
| AHA/ACC 2025 | ESC 2024 | ISH 2020 | |
|---|---|---|---|
| Categories (office) | Normal <120/<80 · Elevated 120–129/<80 · Stage 1 130–139 or 80–89 · Stage 2 ≥140 or ≥90 | Non-elevated <120/70 · Elevated 120–139/70–89 · Hypertension ≥140/90 | Normal <130/85 · High-normal 130–139/85–89 · Grade 1 140–159/90–99 · Grade 2 ≥160/100 |
| Hypertension starts at | ≥130/80 | ≥140/90 | ≥140/90 |
| Home BP threshold for hypertension | ≥130/80 (stage 1), ≥135/85 (stage 2) | ≥135/85 | ≥135/85 |
| Risk calculator | PREVENT (10-year CVD risk) | SCORE2 / SCORE2-OP | Simplified risk table |
| "High risk" cut-off | PREVENT ≥7.5% | SCORE2 ≥10% (or 5–<10% + risk modifiers) | CVD, CKD, diabetes, HMOD |
| Drugs at 130–139/80–89 | Start now if CVD, diabetes, CKD or PREVENT ≥7.5%. Otherwise after 3–6 months of lifestyle if still ≥130/80 | Only if high risk, after 3 months of lifestyle | Lifestyle; drugs only for a compelling indication |
| Target | <130/80, encourage SBP <120 | SBP 120–129, DBP 70–79 if tolerated (ALARA if not) | Essential: ≥20/10 fall, ideally <140/90. Optimal: <130/80 if <65 y; <140/90 if ≥65 y |
| Initial monotherapy is fine for | Stage 1 | Elevated BP, age ≥85, frailty, symptomatic orthostatic hypotension | Low-risk grade 1, very old (≥80), frail |
| Acute ICH | SBP 150–220: lower to 130–<140 and keep ≥7 days | Lower to SBP 140–160 within 6 h | Not covered in detail |
| Renal denervation | 2b (selected resistant HTN) | IIb (medium/high-volume centre); III as first-line | Not covered |
Clinical pearls
- AHA keeps the 2017 categories (stage 1 starts at 130/80). ESC and ISH still define hypertension at ≥140/90.
- AHA 2025 swaps the Pooled Cohort Equations for PREVENT, with a 7.5% 10-year CVD risk threshold.
- ESC 2024 brought in the "elevated BP" category (120–139/70–89) and a target range of 120–129 systolic.
- In acute ICH, AHA aims lower (130–<140) and ESC aims higher (140–160).
- In pregnancy, all three avoid ACE inhibitors and ARBs. Labetalol and extended-release nifedipine are the preferred drugs (ESC also lists methyldopa).